Biophytis (BPTSY)
OTHER OTC:BPTSY
Holding BPTSY?
Track your performance easily

Biophytis (BPTSY) Income Statement

33 Followers

Biophytis Income Statement

Last quarter (Q4 2023), Biophytis's total revenue was €―, a decrease of ― from the same quarter last year. In Q4, Biophytis's net income was €―. See Biophytis’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----€ 0.00€ 0.00
Cost of Revenue
----€ 0.00€ 0.00
Gross Profit
----€ 0.00€ 0.00
Operating Expense
-€ 14.33M€ 23.27M€ 29.40M€ 13.94M€ 15.68M
Operating Income
-€ -14.33M€ -23.27M€ -29.40M€ -13.94M€ -15.68M
Net Non Operating Interest Income Expense
-€ -1.36M€ 983.00K€ 24.00K€ -1.50M€ -1.49M
Other Income Expense
-€ 1.33M€ 23.58M€ 1.88M€ -10.07M€ -1.85M
Pretax Income
-€ -17.03M€ -24.22M€ -31.25M€ -25.52M€ -19.03M
Tax Provision
----€ 0.00€ -80.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-€ -17.03M€ -48.43M€ -62.49M€ -25.52M€ -18.95M
Basic EPS
-€ -0.03€ -0.14€ -0.26€ -2.80€ -10.50
Diluted EPS
-€ -0.03€ -0.14€ -0.26€ -2.80€ -10.50
Basic Average Shares
-€ 543.07M€ 174.84M€ 118.28M€ 6.00M€ 1.69M
Diluted Average Shares
-€ 543.07M€ 345.94M-€ 6.00M€ 1.69M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-€ 14.33M€ 23.27M€ 29.40M€ 13.94M€ 15.68M
Net Income From Continuing And Discontinued Operation
-€ -17.03M€ -48.43M€ -62.49M€ -25.52M€ -18.95M
Normalized Income
-€ -12.51M--€ -15.44M€ -17.10M
Interest Expense
----€ 817.00K€ 1.13M
EBIT
-€ -15.39M€ -24.22M€ -31.25M€ -24.70M€ -17.90M
EBITDA
-€ -14.32M€ -23.73M€ -30.94M€ -24.42M€ -17.64M
Currency in EUR

Biophytis Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis